GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (CHIX:PEGc) » Definitions » Debt-to-Revenue

Pharma Equity Group A/S (CHIX:PEGC) Debt-to-Revenue : N/A (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Pharma Equity Group A/S Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Pharma Equity Group A/S's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr22.15 Mil. Pharma Equity Group A/S's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr8.07 Mil. Pharma Equity Group A/S's annualized Revenue for the quarter that ended in Dec. 2023 was kr0.00 Mil.


Pharma Equity Group A/S Debt-to-Revenue Historical Data

The historical data trend for Pharma Equity Group A/S's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S Debt-to-Revenue Chart

Pharma Equity Group A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Pharma Equity Group A/S Quarterly Data
Mar16 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Pharma Equity Group A/S's Debt-to-Revenue

For the Biotechnology subindustry, Pharma Equity Group A/S's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group A/S's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group A/S's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group A/S's Debt-to-Revenue falls into.



Pharma Equity Group A/S Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Pharma Equity Group A/S's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(22.149 + 8.072) / N/A
=N/A

Pharma Equity Group A/S's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(22.149 + 8.072) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Pharma Equity Group A/S Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group A/S (CHIX:PEGC) Business Description

Traded in Other Exchanges
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.

Pharma Equity Group A/S (CHIX:PEGC) Headlines

No Headlines